CTTH - CTT Pharma Partners with Johns Hopkins University for NIH Grant for a Smoking Cessation Product
(TheNewswire)
Tampa, Florida, United States – The Newswire – March 27, 2024 -CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) has signed an agreementwith Johns Hopkins University for a NIH grant utilizing our patentedtechnology to create fast acting, low dose nicotine strips as asmoking cessation product. The NIH grant is up to $15 million dollarsand would fund human trials over a 3 year period. Johns Hopkins wouldconduct the human trials for smokers looking to quit during thisprocess, which would be done as a Phase 1, Phase 2, and Phase 3 model.CTT Pharma will be involved with the human trials and createdissolvable nicotine strips that would be used to help theparticipants quit in these studies. The main objective of these trialswould be to successfully wean smokers off of cigarettes using ourpatented technology and to do so in a manner where the nicotinedissolves in the mouth in seconds.
Johns Hopkins University has been the highest NIH awarded universityfor many years and continued that trend in 2023 as they led all U.S.universities and colleges in total National Institute Health(NIH)funding, receiving over $842 million in awards. CTT believes theirknowledge and expertise will help gain the necessary funding to helpgive smokers and nicotine consumers a new option to quit.
The World Health Organization states, “The tobacco epidemic is oneof the biggest public health threats the world has ever faced, killingover 8 million people a year around the world. More than 7 million ofthose deaths are results of direct tobacco use while 1.3 million arethe result of non-smokers being exposed to second-hand smoke.” Furthermore, the CDC says, “Cigarette smoking is the leading causeof preventable death in the United States. Cigarette smoking causesmore than 480,000 deaths each year in the United States. This isnearly one in five deaths.”
The CEO of CTT Pharma, Ryan Khouri, stated “This partnership is astep in the right direction as it could ultimately allow smokers theability to choose a low dose, fast dissolving nicotine strip for asmoking cessation product. I believe there’s a real need for ourtechnology as current oral nicotine products stay in the mouth for anexcessive amount of time. I’m confident in our ability to create asuperior product that will help society and look forward to thisopportunity.”
CTT Pharma – 813-606-0060
Copyright (c) 2024 TheNewswire - All rights reserved.